User testimonials

What users say about our instruments

“Single cell efficacy: 70-93%; Colony efficacy: 58-91% (after optimization) […] The plating effort (to get single cells) can be lowered compared to limited dilution and FACS single cell deposition by the factor 4-5 […]”

A. Mayer-Bartschmid, Senior Scientist

bayer

“[cytena’s] cloning platform is suitable for generating clonal cell lines with a probability of ≥99.9%… Overall, the implementation of this novel technology provides significant advantages over traditional methods with respect to cost, simplicity, timing and flexibility.“

C. Lovelady, Senior Scientist

MedImmune_logo

“When using the scp™, the number of monoclonal cell lines increased 6-fold compared to the limiting dilution process, therefore increasing the number of pools that could be cloned… By implementing both of these technologies, the cell line development process can be decreased from 9 months to 6 months.”

A. Mahé, Scientist

novimmune-large